Violette Shelia M. 4

What Happened

• Violette Shelia M., Chief Scientific Officer of Q32 Bio, acquired 37,500 shares on July 16, 2026 through an award/grant (reported as code A) at a reported price of $0.00 (total cash cost $0). The shares represent common stock underlying performance-based restricted stock units (PSUs) granted on July 6, 2026.

Key Details

• Transaction date and price: 2026-07-16, 37,500 shares at $0.00 per share (award/vest).
• Filing date: Form 4 filed 2026-07-20 — appears timely (filed within required business-day window).
• Shares owned after transaction: Not specified in the provided filing.
• Footnote (performance/time vesting): The 37,500 shares represent PSUs that vested on 7/16/2026 with respect to a performance condition tied to closing a financing of at least $100,000,000 on or before 12/31/2026. The PSUs are also subject to a time-based condition: they vest in equal quarterly installments over three years from 7/1/2026, subject to continued service. Each PSU is a contingent right to one share.
• Related-entity disclosure: Some shares are held by Violette Holdings LLC; the reporting person is a manager and disclaims beneficial ownership of those holdings except to the extent of any pecuniary interest.

Context

• These were awarded/vested PSUs (not an open-market purchase or sale). PSUs are contingent/derivative awards that can be subject to both performance and time-based vesting; the filing indicates the performance condition was satisfied as reported but also notes an ongoing time-based vesting schedule. This transaction does not by itself indicate a buy or sell sentiment by the insider.